Valuation : BenevolentAI S.A.

Market Cap 8.34M 11.29M 9.71M 9.13M 15.59M 1.07B 15.64M 108M 41.85M 547M 42.4M 41.47M 1.74B P/E 2023
-1.75x
P/E 2024 -
Enterprise Value -18.83M -25.5M -21.93M -20.63M -35.22M -2.41B -35.33M -245M -94.54M -1.24B -95.77M -93.68M -3.93B EV / Sales 2023
5.72x
EV / Sales 2024 2.15x
Free-Float
59.54%
Yield 2023 *
-
Yield 2024 -
3 years 0.07
Extreme 0.07
2.66
5 years 0.07
Extreme 0.07
10
10 years 0.07
Extreme 0.07
10
Manager TitleAgeSince
Chief Operating Officer 50 2014-01-31
Director of Finance/CFO - 2024-10-15
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 70 2020-06-30
Chairman 70 2024-05-01
Director/Board Member 58 2013-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/24 Buy

Director

10,000 0.0070%
2/9/24 Buy

Director

2,066 0.0014%
2/9/24 Buy

Director

20,000 0.0140%
Change 5-day change 1-year change 3-year change Capi.($)
-14.74%-.--%-.--%-92.21% 11.59M
-1.16%-2.77%-2.91%+13.85% 48.93B
-0.40%+2.16%+418.57%+554.47% 45.01B
-1.42%+2.52%+42.67%+22.27% 44.07B
-1.22%-0.37%+4.82%+84.42% 40.73B
-0.96%-1.38%+15.75%+45.91% 33.52B
-0.21%+2.86% - - 17.77B
-0.35%-0.45%+21.42%+117.63% 16.5B
-1.54%-1.30%+12.16%+31.14% 14.67B
-1.65%+0.09%+75.93%+41.15% 13.77B
Average -2.36%-2.70%+65.38%+90.96% 27.5B
Weighted average by Cap. -1.00%-0.05%+88.95%+134.35%

Financials

2023 2024
Net sales 7.33M 9.93M 8.54M 8.03M 13.71M 939M 13.76M 95.22M 36.81M 481M 37.29M 36.47M 1.53B 5.24M 7.1M 6.11M 5.74M 9.8M 671M 9.84M 68.09M 26.32M 344M 26.66M 26.08M 1.1B
Net income -63.32M -85.75M -73.75M -69.36M -118M -8.11B -119M -822M -318M -4.15B -322M -315M -13.23B -71.82M -97.27M -83.65M -78.68M -134M -9.2B -135M -933M -361M -4.71B -365M -357M -15.01B
Net Debt -68.16M -92.31M -79.39M -74.66M -127M -8.73B -128M -885M -342M -4.47B -347M -339M -14.24B -27.17M -36.79M -31.64M -29.76M -50.81M -3.48B -50.97M -353M -136M -1.78B -138M -135M -5.68B
Logo BenevolentAI S.A.
BenevolentAI SA is engaged in creating and applying artificial intelligence (AI) and machine learning in drug discovery. The Company designs its technology to enable scientists to better understand the development of disease mechanisms, discover drug targets and make decisions. It serves patients by leveraging its proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop drugs for complex diseases. The Benevolent Platform integrates technology, processes, and humans for faster research and development success. Its pipeline includes BEN-8744, BEN-28010, BEN-34712, Parkinson's disease, and Fibrosis. BEN-8744 is developed for the treatment of an ulcerative colitis. The Company provides scientists with a view of disease biology by integrating across all the domains and diverse data types, including omics, molecules, experimental data, literature, pathology, and biological systems.
Employees
173
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!